KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Carrie Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M Reagan, Mark Hertzberg, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Singh, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P Sharman, Neha Mehta-Shah, Christopher R Flowers, Hervé Tilly, Neil Chua, René-Olivier Casasnovas, Fiona Miall, Tae Min Kim, Xavier Cheng-Hong Tsai, Sunita Nasta, Seung Tae Lee, Jonathan W Friedberg

Blood 147(3) 254-265

PMID40997297
PMCIDPMC12824648
DOI10.1182/blood.2025028848
发表日期2025-09-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
已检查 6 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 flow diagram;Figure 2:生活质量量表图;Figure 3:生活质量量表图;Figure 4:生活质量量表图;另有 1 张未列出。
摘要

摘要

Diffuse large B-cell lymphoma (DLBCL) poses a challenge in hematology given its varied symptoms, and the complex interplay between disease and treatment effects on health-related quality of life (HRQoL). The phase 3 POLARIX study demonstrated superior progression-free survival and a similar safety profile with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated DLBCL. Here, we evaluate HRQoL through patient-reported outcome (PRO) instruments to fully characterize the patient experience in the POLARIX study. Changes from baseline in HRQoL, lymphoma symptoms, and gastrointestinal (GI) symptoms were assessed, as well as incidence and severity of common symptoms by PROs vs clinician-reported adverse events (AEs). Baseline characteristics of PRO-evaluable patients (N = 874) were consistent. Comparison between PROs and clinician-reported AEs revealed a notable discordance; patients generally reported a higher incidence of symptoms than clinicians, emphasizing the need for patient-centric tools to accurately capture the patient experience. Both treatments exhibited rapid and sustained improvements in HRQoL and lymphoma symptoms, with the most substantial improvements seen in global health status/QoL, lymphoma symptoms, fatigue, role, emotional, and social functioning. GI symptoms (diarrhea, constipation, nausea, and vomiting) were generally similar between treatment arms and returned to baseline levels after treatment completion. These HRQoL data underscore the complementarity of PROs, as an adjunct to clinician-reported AEs, in evaluating the efficacy and tolerability of new treatments, including Pola-R-CHP, which may represent a new benchmark for patient-reported HRQoL in previously untreated DLBCL. This trial was registered at www.clinicaltrials.gov as NCT03274492.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. Schedule of PRO administration and clinician-reported AE in POLARIX. ∗EOT occurred 6 to 8 weeks after the last dose of study treatment. †Defined as new or worsening AEs from the first dose of any study drug up until 90 days after the last dose of any study drug, or before new antilymphoma therapy. NCI, National Cancer Institute.
非 KM Figure
Figure 2Figure 2. Incidence of symptoms and symptom severity by PROs∗ and clinician-reported AEs†. ∗PROs symptom severity was based on the highest EORTC QLQ-C30 score reported out of clinic visits on day 1 of cycle 1, 2, 3, and 5, and at EOT; multiple occurrences of the same symptom in 1 individual were counted once at the highest score for that patient. †Clinician-reported symptom severity was based on the highest-grade AEs reported by NCI-CTCAE version 4.0 during the AE reporting period; multiple occurrences of the same AE in 1 individual were counted once at the highest grade for that patient. ‡Grade 4 constipation events occurred in 0.1% of patients. NCI, National Cancer Institute.
非 KM Figure
Figure 3Figure 3. EORTC QLQ-C30 score for gastrointestinal symptoms. (A) Diarrhea; (B) constipation; (C) nausea; and (D) vomiting. Abbreviations: C, cycle; D, day.
非 KM Figure
Figure 4Figure 4. Mean change from baseline in EORTC QLQ-C30 in GHS/QoL (A), physical functioning (B), role functioning (C), emotional functioning (D), social functioning (E), fatigue (F), and cognitive functioning (G) and in FACT-Lym LYMS in lymphoma symptoms (H). Abbreviations: C, cycle; D, day.
非 KM Figure
Figure 5Figure 5. Clinically meaningful differences in EORTC QLQ-C30 for GHS/QoL (A), physical functioning (B), role functioning (C), emotional functioning (D), social functioning (E), fatigue (F), and cognitive functioning (G) and in FACT-Lym LYMS in lymphoma symptoms (H). Abbreviations: C, cycle; D, day.
非 KM Figure